Last Updated : September 20, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | ||
Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
Neupro | Rotigotine | Parkinson's disease | Do not list | Complete | ||
Neupro | Rotigotine | Parkinson’s disease | List with clinical criteria and/or conditions | Complete | ||
Nexavar | Sorafenib | Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) | Do not reimburse | Complete | ||
Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
Nexplanon | etonogestrel | Prevention of pregnancy | Reimburse with clinical criteria and/or conditions | Complete | ||
Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Ninlaro | Ixazomib | Multiple Myeloma (2nd-beyond) | Do not reimburse | Complete | ||
Ninlaro | Ixazomib | Multiple Myeloma | Do not reimburse | Complete | ||
Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete | ||
NovoMix 30 | Insulin aspart/insulin aspart protamine | Diabetes mellitus | Do not list | Complete | ||
Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete | ||
Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Severe chronic rhinosinusitis with nasal polyps | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Eosinophilic granulomatosis with polyangiitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Nucala | mepolizumab | Asthma, severe eosinophilic (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Nucala | Mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete |